← Back to Search

Behavioral Intervention

DREAMLAND for Acute Myeloid Leukemia

N/A

Waitlist Available

Led By Areej El-Jawahri, MD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

Study Summary

This trial is testing if a psychological mobile app can help reduce anxiety and depression symptoms and improve quality of life for patients with acute myeloid leukemia.

Eligible Conditions

Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Anxiety Symptoms

Depression Symptoms

Post-Traumatic Stress Disorder (PTSD) Symptoms

+2 more

Other outcome measures

Coping

Health care utilization

Self-efficacy

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: DREAMLANDExperimental Treatment1 Intervention

Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA. Participants will use DREAMLAND and during hospitalization for treatment of AML to learn how to cope most effectively with the diagnosis of AML using an iPad provided by the study team or participant's own iPad. Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days.

Group II: CERENAActive Control1 Intervention

Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA. Participants will use the mobile app CERENA during hospitalization for treatment of AML to learn how to best care for themselves using an iPad provided by the study team or participant's own iPad. Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Blue Note TherapeuticsIndustry Sponsor

6 Previous Clinical Trials

770 Total Patients Enrolled

Massachusetts General HospitalLead Sponsor

2,928 Previous Clinical Trials

13,198,344 Total Patients Enrolled

Areej El-Jawahri, MDPrincipal InvestigatorMassachusetts General Hospital

18 Previous Clinical Trials

4,501 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the capacity of this scientific research study?

"Affirmative, the information posted on clinicaltrials.gov verifies that this medical trial is presently looking for participants to participate in their research. This study was initially published on October 15th 2022 and has since been amended as of November 17th 2022. The experiment requires 180 volunteers from a single location to take part in it."

Answered by AI

Are recruitment efforts ongoing for this trial?

"Correct. Information sourced from clinicaltrials.gov confirms that this research project is still recruiting participants, with 180 needing to be found at a single site. The trial was originally posted on October 15th 2022 and its details were most recently updated on November 17th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Psychological Mobile App for Patients With AML

El-Jawahri, Areej,M.D. 2022. "Psychological Mobile App for Patients With AML". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05501171.